Enovis Corporation (NYSE:ENOV) Given Average Rating of “Moderate Buy” by Analysts

Enovis Corporation (NYSE:ENOV) has been assigned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $46.7143.

ENOV has been the topic of several analyst reports. UBS Group reiterated a “buy” rating and set a $50.00 target price on shares of Enovis in a report on Monday, January 5th. Wells Fargo & Company lifted their price objective on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Evercore restated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Canaccord Genuity Group dropped their price target on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Finally, BTIG Research assumed coverage on shares of Enovis in a research report on Tuesday, January 6th. They issued a “buy” rating and a $41.00 price objective for the company.

Insider Activity at Enovis

In related news, EVP Daniel A. Pryor sold 999 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.70% of the company’s stock.

Institutional Trading of Enovis

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Arax Advisory Partners acquired a new position in shares of Enovis in the 4th quarter worth approximately $29,000. Farther Finance Advisors LLC lifted its stake in Enovis by 42.8% during the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after purchasing an additional 367 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in Enovis during the second quarter valued at $46,000. Finally, SJS Investment Consulting Inc. raised its holdings in shares of Enovis by 30,340.0% during the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after purchasing an additional 1,517 shares during the period. 98.45% of the stock is owned by institutional investors.

Enovis Stock Down 1.5%

Shares of NYSE ENOV opened at $22.39 on Tuesday. The stock has a fifty day moving average price of $24.50 and a 200 day moving average price of $28.31. The company has a current ratio of 2.22, a quick ratio of 1.16 and a debt-to-equity ratio of 0.66. Enovis has a 12-month low of $21.00 and a 12-month high of $43.76. The company has a market cap of $1.28 billion, a P/E ratio of -0.95 and a beta of 1.52.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.